Clinical Trial Update: Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 study of oral forodesine hydrochloride (BCX-1777) in patients with recurrent or refractory T/NK-cell malignancies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Natural Killer Cell Leukemia
• Natural Killer Cell Lymphoma
• T-cell Lymphoma

Drugs mentioned

• Forodesine hydrochloride (forodesine hydrochloride)

Snippet

Sponsor: Mundipharma K.K. | Conditions: Recurrent or Refractory T/NK-cell Malignancies | Phase 1 | Status: COMPLETED